ProCE Banner Activity

Phase III DEB Trial: Interim Analysis of Tucidinostat + R-CHOP vs R-CHOP Alone as 1L Tx in MYC and BCL2 Double-Expressing DLBCL

Conference Coverage
Slideset

Interim analysis of the phase III DEB trial of tucidinostat plus R-CHOP vs R-CHOP plus placebo in patients with MYC and BCL2 double-expressing DLBCL reported significantly longer EFS with the addition of tucidinostat.

Released: June 06, 2024

Expiration: June 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

GSK

Lilly

Novartis Pharmaceuticals Corporation

Sanofi